C-reactive protein and bacterial infection in cirrhosis

Annals of Gastroenterology

Volumn 27, Issue 2, 2014, Pages 113-120

  Pieri, Giulia ^a   Agarwal, Banwari ^b   Burroughs, Andrew K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bacterial infections; C reactive protein; Cirrhosis; Intensive care unit; Mortality; Prognosis

Indexed keywords

C REACTIVE PROTEIN;

ALCOHOL LIVER DISEASE; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PERITONITIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE STORM; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PATHOGENESIS; PROGNOSIS; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPSIS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84897079073     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxix. Hepatology 2002;35:140-148.
2. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005;54:718-725.
3. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010;139:1246-1256.
4. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 2009;50:2022-2033.
5. Foreman MG, Mannino D, Moss M. Cirrhosis as a rick factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003;124:1016-1020.
6. Plessier A, Denninger MH, Consigny Y, et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int 2003;23:440-448.
7. Wiest R, Garcia-Tsao G. Bacterial translocation in cirrhosis. Hepatology 2005;41:422-433.
8. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. Hepatology 2012;S2-S12.
9. Deviere J, Content J, Denys C, et al. Excessive in vitro bacterial lipolysaccharide-induced production of monkines in cirrhosis. Hepatology 1990;11:628-634.
10. Navasa M, Follo A, Fiella X, et al. Tumor necrosis factor and interleukin 6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the developmente of renal impairment and mortality. Hepatology 1998;27:1227-1232.
11. Bone RC, Grodzin C, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-243.
12. Bernard B, Grange J, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotics prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastroeintestinal bleeding: a metaanalysis. Hepatology 1999;29:1655-1661.
13. Yoshida H, Hamada T, Inuzuka S, Ueno T, Sata M, Tanikawa K. Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. Am J Gastroent 1993;88:2067-2071.
14. Llach J, Rimola A, Navara M, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992;16:724-727.
15. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a doubleblind, placebo-controlled trial. Hepatology 1990;12:716-724.
16. Rimola A, Garcia-Tao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites club. J Hepatol 2000;32:142-153.
17. Tandon P, Garcia-Tao G. Bacterial infections, sepsis and multiorgan failure in cirrhosis. Semin Liver Dis 2008;28:26-42.
18. American College of Chest Physicians/Society of Critical Care Medicine. Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
19. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009;51:475-482.
20. Thabut D, Massard J, Gangloff A, et al. Model for end-stage liver disease score and systemic inflammatoru response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007;46:1872-1882.
21. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem 2009;48:111-136.
22. Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004;8:R234-R242.
23. Chauveau P, Level C, Lasseur C, et al. C-reactive protein and procalcitonin as markers of mortaloty in hemodialysis patients: a 2-year prospective study. J Ren Nutr 2003;13:137-143.
24. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
25. Mendall MA, Strachan D, Butland BK, et al. C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-1590.
26. Bota DP, van Nuffelen M, Zakariah AH, Vincent JL. Serum level of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab CLin Med 2005;146:347-351.
27. Imhof A, Froehlich M, Boeing H, et al. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001;357:763-767.
28. Hirschfield GM, Pepys M. C-reactive protein and cardiovascular disease: new insights from an old molecule. Q J Med 2003;96:793-807.
29. Westhuyzen J, Healy H. Review: Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci 2000;30:133-143.
30. Vigushin DM, Pepys M, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human c-reactive protein in health and disease. J Clin Invest 1993;91:1351-1357.
31. Vanbiervliet G, Le Breton F, Rosenthal-Allieri MA, et al. Serum C-reactive protein: A non-invasive marker of alcoholic hepatitis. Scand J Gastroent 2006;41:1473-1479.
32. Fujimoto M, Uemura M, Kojima H, et al. Prognostic factors in severe alcoholic liver injury. Nara Liver Study Group. Alcohol Clin Exp Res 1999;23(4 Suppl):33S-38S.
33. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver disease. Gastroenterology 1992;103:264-274.
34. Le Moine O, Deviere J, Devaster JM, et al. Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis. J Hepatol 1994;20:819-824.
35. Albillos A, de la Hera A, Gonzales M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and haemodynamic derangement. Hepatology 2003;37:208-217.
36. Marquez M, Fernandez-Gunerrez C, Montes-deoca M, et al. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clin Exp Immunol 2009;158:219-229.
37. Campillo B, Sherman E, Richardet JP, Bories PN. Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism. Eur J Clin Nutrition 2001;55:980-988.
38. Meliconi R, Parracino O, Facchini A, et al. Acute phase protein in chronic and malignant liver diseases. Liver 1988;8:65-74.
39. Janum SH, Sovso M, Gradel KO, Schonheyder HC, Nielsen H. C-reactive protein level as a predictor of mortality in liver disease patients with bacteremia. Scand J Gastroent 2011;46:1478-1483.
40. Papp M, Vitalis Z, Altorjay I, et al. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infection. Liver Int 2011;603-611.
41. Park WB, Lee K, Lee CS, et al. Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. Diagn Microbiol Infect Dis 2005;51:227-230.
42. Pavoa P. C-reative protein: a valuable marker of sepsis. Intensive Care Med 2002;28:235-243.
43. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
44. Grander W, Dunser M, Stollenwerk B, et al. C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients. Chest 2010;38:856-862.
45. Cholongitas E, Senzolo M, Patch D, et al. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther 2006;23:883-893.
46. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426-1437.
47. Wehler M, Kokoska J, Reulbach U, et al. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 2001;34:255-261.
48. Mackenzie I, Woodhouse J. C-reactive protein concentrations during bacteraemia: a comparison between patients with and without liver dysfunction. Intensive Care Med 2006;32:1344-1351.
49. Cervoni JP, Thevenot T, Weil D, et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012;6:1299-1304.
50. Li CH, Yang R, Pang JH, et al. Procalcitonin as a biomarker for bacterial infection in patients with liver cirrhosis in the emergency department. Acad Emerg Med 2011;18:121-126.
51. Lazzarotto C, Ronsoni M, Fayad L, et al. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol 2013;12:599-607.
52. Ha YE, Kang C, Joo EJ, et al. Usefulness of C-reactive protein for evaluating clinical outcomes in cirrhotic patients with bacteremia. Korean J Intern Med 2011;26:195-200.
53. Lin ZY, Chuang W, Dai CY, et al. Clinical application of c-reactive protein measerement in the detection of bacterial infection in patiets with liver cirrhosis. Kaohsiung J Med Sci 2002;18:121-126.
54. Viallon A, Zeni F, Puozet V, et al. Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines. Intensive Care Med 2000;26:1082-1088.
55. Tsiakalos A, Karatzaferis A, Ziakas P, and Hatzis G. Acute phase protein as indicators of bacterial infection in patients with cirrhosis. Liver Int 2009;1538-1542.
56. Kwon JH, Jang J, Lee S, et al. Diagnostic performance of C-reactive protein and neutrophils-to-lymphocyte ratio for inferction in patietns with decompensated cirrhosis. Abstract 207, EASL 2013, 2013.
57. Zheng Z, Zhou L, Gao S, Yang Z, Yao J, Zheng S. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci 2013;10:653-664.
58. Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 2013;20:325-339.
59. An HJ, Jang J, Bae SH, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2012;18:1406-1414.
60. Tang BM, Eslick G, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-217.
61. O'Grady NP, Barie P, Bartlett JG, et al. American College of Critical Care Medicine; Infectious Diseases Society of America. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 2008;36:1330-1340.
62. Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In Critically Ill Patients, Serum Procalcitonin Is More Useful in Differentiating between Sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract 2011;2011:594645.
63. Zapater P, Frances R, Gonzalez-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfectes patients with cirrhosis. J Hepatol 2008;48:1924-1931.
64. Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013;33:31-39.